March 17–21, 2026 | Copenhagen, Denmark

StageBio is pleased to attend AD/PD™ 2026, one of the world's foremost conferences dedicated to Alzheimer's disease, Parkinson's disease, and related neurodegenerative conditions. Our team will be on the ground in Copenhagen, connecting with sponsors and researchers who are advancing some of the most important programs in CNS drug development today.

About AD/PD™ 2026

AD/PD™ is where the brightest minds in neurodegeneration gather to explore the latest research, clinical trials, and emerging treatments for Alzheimer's and Parkinson's disease. The conference brings together leading scientists, clinicians, and industry professionals to share groundbreaking discoveries and shape the future of neurodegenerative medicine. For drug developers advancing CNS programs, it is one of the most important gatherings of the year.

Specialist Neuropathology Support for CNS and PNS Programmes

As CNS and PNS programs move toward IND-enabling toxicology and key regulatory milestones, robust, well-interpreted tissue data becomes critical. StageBio provides specialist neuropathology support across preclinical safety, efficacy, and translational studies, delivering high-quality histopathology with regulatory-ready reporting and fast turnaround times.

Whether you are working in neurodegeneration, neurotoxicity, demyelination, or related indications, our team of board-certified pathologists and neuropathology specialists is equipped to support your program from early discovery through submission.

StageBio Neuropathology Capabilities

• Board-certified CNS and PNS pathologists supporting neurodegeneration, neurotoxicity, demyelination, and developmental models

• Expert brain and spinal cord trimming, ganglia and nerve dissection optimised for gliosis, inflammation, and axonal injury assessment

• Advanced biomarker and IHC panels, including NeuN, MAP2, GFAP, Iba1, MBP, Luxol Fast Blue, alpha-synuclein, tau, amyloid, and TDP-43

• Specialty stains, including Congo Red, Bielschowsky Silver, and LDH for plaque, tangle, and ischemia evaluation

• Intraepidermal Nerve Fibre (IENF) analysis for quantitative small fibre assessment in neuropathy and neurotoxicity studies

• Digital pathology and image analysis to complement expert semi-quantitative pathology interpretation

• GLP-compliant, IND/IMPD-enabling data packages with SEND-ready reporting

If you are progressing a CNS program toward toxicology or submission, we would be pleased to discuss how StageBio's neuropathology expertise can strengthen your tissue endpoints and support confident development decisions.

Meet Garek Wilashko

Garek Wilashko Business Development Garek Wilashko serves as a strategic partner for drug developers navigating the histopathology phase of their preclinical programs. He works to connect clients with the right scientific experts, help shape study designs aligned to program goals, and ensure all critical pieces are in place for projects to move forward efficiently. His focus is on helping sponsors avoid common missteps, identify tailored solutions, and obtain the clarity and precision their tissue-based studies require.

Attending AD/PD™ 2026? Garek welcomes the opportunity to connect with colleagues and collaborators throughout the conference.

Let's Connect in Copenhagen

Whether you're attending AD/PD™ 2026 or simply want to learn more about StageBio's neuropathology capabilities, we'd love to hear from you.

Garek Wilashko and the StageBio team are available to discuss your CNS or PNS program needs, explore how our neuropathology services can support your next study, or simply connect with fellow scientists and developers invested in advancing neurodegeneration research.

Contact us to learn more about StageBio's Neuropathology Services.

StageBio is a leading preclinical contract research organization specializing in pathology, toxicology, and neuropathology services. We are committed to supporting the scientific community through rigorous research, expert consultation, and meaningful engagement, at conferences like AD/PD™ 2026 and every day in our labs.